Ephraim E Parent1, Ila Sethi2, Jonathon Nye3, Chad Holder3, Jeffrey J Olson4, Jeffrey Switchenko5, Funmilayo Tade6, Oladunni O Akin-Akintayo3, Olayinka A Abiodun-Ojo3, Akinyemi Akintayo3, David M Schuster3. 1. Department of Radiology, Mayo Clinic, Jacksonville, FL, USA. 2. Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, GA, USA - sila2@emory.edu. 3. Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, GA, USA. 4. Department of Neurosurgery, Emory University School of Medicine, Atlanta, GA, USA. 5. Bioinformatics and Biostatistics Shared Resource, Winship Cancer Institute of Emory University, Atlanta, GA, USA. 6. Department of Radiology, Loyola University, Chicago, IL, USA.
Abstract
BACKGROUND: Accurate identification and discrimination of post treatment changes from recurrent disease remains a challenge for patients with intracranial malignancies despite advances in molecular and magnetic resonance imaging. We have explored the ability of readily available Rubidium-82 chloride (82RbCl) positron emission tomography (PET) to identify and distinguish progressive intracranial disease from radiation necrosis in patients previously treated with radiation therapy. METHODS: Six patients with a total of 9 lesions of either primary (N.=3) or metastatic (N.=6) intracranial malignancies previously treated with stereotactic radiation surgery (SRS) and persistent contrast enhancement on MRI underwent brain 82RbCl PET imaging. Two patients with arteriovenous malformations previously treated with SRS, also had brain 82RbCl PET imaging for a total of 11 lesions studied. Histological confirmation via stereotactic biopsy/excisional resection was obtained for 9 lesions with the remaining 2 classified as either recurrent tumor or radiation necrosis based on subsequent MRI examinations. 82RbCl PET time activity curve analysis was performed which comprised lesion SUV<inf>max</inf>, contralateral normal brain SUV<inf>max</inf>, and tumor to background ratios (TB<inf>max</inf>). RESULTS: 82RbCl demonstrates uptake greater than normal brain parenchyma in all lesions studied. Time activity curves demonstrated progressive uptake of 82RbCl in all lesions without evidence of washout. While recurrent disease demonstrated a greater mean SUV<inf>max</inf> compared to radiation necrosis, no statistically significant difference between lesion SUV<inf>max</inf> nor TB<inf>max</inf> was found (P>0.05). CONCLUSIONS: 82RbCl PET produces high-contrast uptake of both recurrent disease and radiation necrosis compared to normal brain. However, no statistically significant difference was found between recurrent tumor and radiation necrosis.
BACKGROUND: Accurate identification and discrimination of post treatment changes from recurrent disease remains a challenge for patients with intracranial malignancies despite advances in molecular and magnetic resonance imaging. We have explored the ability of readily available Rubidium-82 chloride (82RbCl) positron emission tomography (PET) to identify and distinguish progressive intracranial disease from radiation necrosis in patients previously treated with radiation therapy. METHODS: Six patients with a total of 9 lesions of either primary (N.=3) or metastatic (N.=6) intracranial malignancies previously treated with stereotactic radiation surgery (SRS) and persistent contrast enhancement on MRI underwent brain 82RbCl PET imaging. Two patients with arteriovenous malformations previously treated with SRS, also had brain 82RbCl PET imaging for a total of 11 lesions studied. Histological confirmation via stereotactic biopsy/excisional resection was obtained for 9 lesions with the remaining 2 classified as either recurrent tumor or radiation necrosis based on subsequent MRI examinations. 82RbCl PET time activity curve analysis was performed which comprised lesion SUV<inf>max</inf>, contralateral normal brain SUV<inf>max</inf>, and tumor to background ratios (TB<inf>max</inf>). RESULTS: 82RbCl demonstrates uptake greater than normal brain parenchyma in all lesions studied. Time activity curves demonstrated progressive uptake of 82RbCl in all lesions without evidence of washout. While recurrent disease demonstrated a greater mean SUV<inf>max</inf> compared to radiation necrosis, no statistically significant difference between lesion SUV<inf>max</inf> nor TB<inf>max</inf> was found (P>0.05). CONCLUSIONS: 82RbCl PET produces high-contrast uptake of both recurrent disease and radiation necrosis compared to normal brain. However, no statistically significant difference was found between recurrent tumor and radiation necrosis.
Authors: Ramon F Barajas; Jamie S Chang; Mark R Segal; Andrew T Parsa; Michael W McDermott; Mitchel S Berger; Soonmee Cha Journal: Radiology Date: 2009-09-29 Impact factor: 11.105
Authors: Garry Ceccon; Philipp Lohmann; Gabriele Stoffels; Natalie Judov; Christian P Filss; Marion Rapp; Elena Bauer; Christina Hamisch; Maximilian I Ruge; Martin Kocher; Klaus Kuchelmeister; Bernd Sellhaus; Michael Sabel; Gereon R Fink; Nadim J Shah; Karl-Josef Langen; Norbert Galldiks Journal: Neuro Oncol Date: 2017-02-01 Impact factor: 12.300
Authors: Michael Weller; Martin van den Bent; Jörg C Tonn; Roger Stupp; Matthias Preusser; Elizabeth Cohen-Jonathan-Moyal; Roger Henriksson; Emilie Le Rhun; Carmen Balana; Olivier Chinot; Martin Bendszus; Jaap C Reijneveld; Frederick Dhermain; Pim French; Christine Marosi; Colin Watts; Ingela Oberg; Geoffrey Pilkington; Brigitta G Baumert; Martin J B Taphoorn; Monika Hegi; Manfred Westphal; Guido Reifenberger; Riccardo Soffietti; Wolfgang Wick Journal: Lancet Oncol Date: 2017-05-05 Impact factor: 41.316
Authors: Tracy Ssali; Udunna C Anazodo; Jonathan D Thiessen; Frank S Prato; Keith St Lawrence Journal: J Nucl Med Date: 2018-03-09 Impact factor: 10.057